Treat and extend compared to pro re nata regimen in neovascular age-related macular degeneration

Treat and extend compared to pro re nata regimen in neovascular age-related macular degeneration

INTRODUCCIÓN La degeneración macular asociada a la edad es la principal causa de ceguera en personas mayores en el mundo. El tratamiento más eficaz consiste en inyecciones intravítreas de fármacos anti factor del crecimiento vascular endotelial (anti-VEGF). Sin embargo, no existe consenso sobre su...

Full description

Bibliographic Details
Main Author:	Rodolfo Garretón
Format:	Article
Language:	English
Published:	Medwave Estudios Limitada 2020-08-01
Series:	Medwave
Subjects:	age-related macular degeneration treat and extend pro re nata neovascular epistemonikos grade
Online Access:	https://www.medwave.cl/link.cgi/Medwave/PuestaDia/ResEpis/6000.act

Similar Items

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
by: Huixun Jia, et al.
Published: (2022-06-01)

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
by: Andi Arus Victor, et al.
Published: (2022-09-01)

Preserving visual acuity: a compelling 12-year case study of controlling neovascular age-related macular degeneration
by: Rita O. Tomás, et al.
Published: (2024-03-01)

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
by: Yoshihiro Takamura, et al.
Published: (2021-12-01)

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
by: Alaa Din Abdin, et al.
Published: (2021-12-01)

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan
by: Cheng-Kuo Cheng, et al.
Published: (2022-01-01)

Aflibercept versus dexamethasone for macular edema secondary to central retinal vein occlusion
by: Rodolfo Garretón, et al.
Published: (2019-12-01)

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial
by: Praveen J. Patel, et al.
Published: (2020-06-01)

Safety and efficacy of different loading doses followed by pro re nata regimens of Conbercept in the treatment of diabetic macular edema
by: Ting Meng, et al.
Published: (2023-01-01)

Aflibercept compared with dexamethasone in diabetic macular edema
by: Rodolfo Garretón, et al.
Published: (2021-05-01)

Interpretation of Consensus on the Optimal Treat-and-Extend Regimen of Neovascular Age-Related Macular Degeneration(2022 Taiwan, China)
by: Bin Wang, et al.
Published: (2022-09-01)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
by: Khanani AM, et al.
Published: (2019-02-01)

Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration
by: Murat Karaçorlu, et al.
Published: (2019-10-01)

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting
by: Athanasios Vardarinos, et al.
Published: (2017-04-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Fixed Quarterly Dosing of Aflibercept after Loading Doses in Neovascular Age-Related Macular Degeneration in Chinese Eyes
by: Daniel H. T. Wong, et al.
Published: (2023-12-01)

Pharmacoeconomic analysis of anti-VEGF therapy for age-related macular degeneration
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment
by: Joko T, et al.
Published: (2020-03-01)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
by: Patel PJ, et al.
Published: (2017-11-01)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019-07-01)

The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the “Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)” project
by: Yoshitaka Kyou, et al.
Published: (2022-12-01)

Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration
by: Hamidreza Torabi, et al.
Published: (2018-01-01)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021-06-01)

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
by: Mahmut Kaya, et al.
Published: (2023-02-01)

Early detection of choroidal neovascularization in age related macular degeneration
by: Tural Galbinur
Published: (2014-07-01)

Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review
by: Mojtaba Vaismoradi, et al.
Published: (2018-08-01)

Characterizing Macular Neovascularization in Myopic Macular Degeneration and Age-Related Macular Degeneration Using Swept Source OCTA
by: Sayah DN, et al.
Published: (2023-12-01)

Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
by: So Young Han, et al.
Published: (2015-02-01)

Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
by: Daniel Ahmed, et al.
Published: (2020-09-01)

Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
by: Chu-Hsuan Huang, et al.
Published: (2023-11-01)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Rush RB
Published: (2023-08-01)

Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration
by: Jing Wu, et al.
Published: (2022-04-01)

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
by: Helene O. Larsen, et al.
Published: (2023-07-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
by: Reem H. ElSheikh, et al.
Published: (2022-11-01)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Rush RB, et al.
Published: (2022-12-01)

Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018
by: Catherine P. Creuzot-Garcher, MD, PhD, et al.
Published: (2022-03-01)

Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
by: Pengxiang Zhou, et al.
Published: (2021-10-01)

Long-term outcomes of Ranibizumab treatment in neovascular age-related macular degeneration
by: Burak Simsek, et al.
Published: (2018-02-01)

Macular Hemorrhage Due to Age-Related Macular Degeneration or Retinal Arterial Macroaneurysm: Predictive Factors of Surgical Outcome
by: Mitta Pierre, et al.
Published: (2021-12-01)